NASDAQ:GRNA GreenLight Biosciences (GRNA) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free GRNA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.30▼$0.3050-Day Range$0.30▼$0.3052-Week Range$0.18▼$5.90Volume732 shsAverage Volume486,986 shsMarket Capitalization$45.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get GreenLight Biosciences alerts: Email Address Ad InvestorPlaceThe Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story. About GreenLight Biosciences Stock (NASDAQ:GRNA)FUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.Read More Ad InvestorPlaceThe Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story. GRNA Stock News HeadlinesApril 21, 2024 | washingtonpost.comGreenlight Coupon CodesDecember 20, 2023 | bbc.comSplashdown Quaywest gets green light for £3m upgradeApril 25, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.September 28, 2023 | bbc.comBroadwalk Shopping Centre redevelopment given green lightSeptember 19, 2023 | forbes.comGreenlight Family Cash Card 2023 ReviewJuly 24, 2023 | finanznachrichten.deGreenLight Biosciences: GreenLight Announces Completion of Merger with Fall Line Endurance FundJuly 24, 2023 | finance.yahoo.comGreenLight Announces Completion of Merger with Fall Line Endurance FundJuly 20, 2023 | finance.yahoo.comGreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding SharesApril 25, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.June 13, 2023 | bizjournals.comRNA company to lay off 96 employees in LexingtonJune 5, 2023 | benzinga.comGRNA ALERT: Levi & Korsinsky, LLP Announces an Investigation of Greenlight BiosciencesJune 1, 2023 | bizjournals.comRTP biotech went public a year ago. Now, it's being acquiredJune 1, 2023 | bizjournals.comThe Petri Dish: GreenLight to go private; C4 licenses cancer drug for $392MMay 31, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating GreenLight Biosciences Holdings BuyoutMay 30, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether GreenLight Biosciences Holdings, PBC has obtained a Fair Price in its transaction with Fall LineMay 30, 2023 | msn.comGreenLight Biosciences trades 36% higher on merger agreement with Fall Line Endurance FundMay 30, 2023 | finance.yahoo.comGreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private TransactionMay 12, 2023 | msn.comRecap: GreenLight Biosciences Q1 EarningsMay 12, 2023 | msn.comGreenLight Biosciences GAAP EPS of -$0.19 beats by $0.08, revenue of $3.82M beats by $3.32MMay 11, 2023 | finance.yahoo.comGreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company ProgressApril 12, 2023 | finance.yahoo.comGreenLight Biosciences Releases Inaugural Sustainability ReportApril 1, 2023 | seekingalpha.comGreenLight Biosciences draws private equity interest; up 10%March 30, 2023 | finance.yahoo.comGreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall LineMarch 28, 2023 | finance.yahoo.comGreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial ResultsMarch 9, 2023 | finance.yahoo.comGreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D DayMarch 7, 2023 | finance.yahoo.comGreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D DayMarch 4, 2023 | bbc.co.ukGreenlight Screenwriting LabSee More Headlines Receive GRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GreenLight Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GRNA CUSIPN/A CIK1822691 Webwww.eiacorp.com Phone(760) 809-8079FaxN/AEmployees280Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-167,050,000.00 Net Margins-1,521.00% Pretax Margin-1,510.44% Return on Equity-374.26% Return on Assets-122.78% Debt Debt-to-Equity Ratio0.49 Current Ratio1.21 Quick Ratio1.21 Sales & Book Value Annual Sales$10.20 million Price / Sales4.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book0.94Miscellaneous Outstanding Shares151,681,000Free Float105,722,000Market Cap$45.43 million OptionableNot Optionable Beta1.44 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesEthan ZachadnykPresident, CEO, CFO & DirectorKey CompetitorsQuince TherapeuticsNASDAQ:QNCXDyadic InternationalNASDAQ:DYAICidara TherapeuticsNASDAQ:CDTXSAB BiotherapeuticsNASDAQ:SABSOKYO PharmaNASDAQ:OKYOView All Competitors This page (NASDAQ:GRNA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GreenLight Biosciences Holdings Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
